Keyphrases
Putative Drug Targets
100%
Short QT Syndrome
100%
Arrhythmogenic Effect
100%
KCNQ1 mutation
100%
KCNQ1
83%
Action Potential
50%
Adrenergic Stimulation
50%
Computational Simulation
33%
IK Channel
33%
Potential Simulation
33%
Gain-of-function mutation
16%
Pore-forming Subunit
16%
Endocardium
16%
Antiarrhythmic Drugs
16%
Epicardial
16%
Computational Model
16%
Drug Choice
16%
Gain-of-function
16%
Xenopus Oocytes
16%
Ventricular Myocytes
16%
Action Potential Duration
16%
Beta-blockers
16%
Markov Model
16%
Pharmacological Treatment
16%
Fatal Arrhythmia
16%
Current Density
16%
Deactivation
16%
Fast Activation
16%
Rate Dependence
16%
Gating Properties
16%
Gating Mechanism
16%
Conductance-voltage
16%
Fast-slow
16%
Voltage Curve
16%
Pharmacologic Targets
16%
KCNE1
16%
Electrical Heterogeneity
16%
Human Ventricular Myocyte
16%
Biochemistry, Genetics and Molecular Biology
Short QT Syndrome
100%
Wild Type
50%
Action Potential
50%
Adrenergic Stimulation
50%
Electric Potential
16%
Conductance
16%
Cardiac Dysrhythmia
16%
Xenopus
16%
Action Potential Duration
16%
Gain of Function Mutation
16%
Current Density
16%
Antiarrhythmic Agent
16%
KCNE1
16%
Pharmacology, Toxicology and Pharmaceutical Science
Short QT Syndrome
100%
Intermediate Conductance Calcium Activated Potassium Channel
33%
Xenopus
16%
Heart Arrhythmia
16%
Antiarrhythmic Agent
16%
Potassium Channel KCNE1
16%